Rigel Pharmaceuticals (RIGL) Net Equity Issued and Repurchased (2010 - 2018)

Rigel Pharmaceuticals' Net Equity Issued and Repurchased history runs 9 years deep, the most recent figure standing at $8.8 million for Q2 2018.

• On a quarterly basis, Net Equity Issued and Repurchased rose 183.38% year-over-year to $8.8 million in Q2 2018; TTM through Dec 2018 was $14.5 million, a 73.44% decrease from a year earlier, with the FY2018 full-year figure at $67.2 million, down 41.18% from the prior year.
• Net Equity Issued and Repurchased grew to $8.8 million in Q2 2018 per RIGL's latest filing, from $5.7 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $43.1 million in Q1 2017 and bottomed at $5000.0 in Q3 2014.
• The 5-year median for Net Equity Issued and Repurchased is $2.6 million (2017), against an average of $6.5 million.
• Across the five-year window, Net Equity Issued and Repurchased jumped 32252.94% in 2016 and sank 91.44% in 2017, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at $480000.0 in 2014, then surged by 767.71% to $4.2 million in 2015, then tumbled by 68.79% to $1.3 million in 2016, then jumped by 338.46% to $5.7 million in 2017, then surged by 53.72% to $8.8 million in 2018.
• Per Business Quant, the three latest RIGL Net Equity Issued and Repurchased figures stand at $8.8 million (Q2 2018), $5.7 million (Q4 2017), and $2.6 million (Q3 2017).